WITHDRAWAL OF MAINTENANCE ANTIPARKINSON DRUG IN THE PHENOTHIAZINE-INDUCED EXTRAPYRAMIDAL REACTION
Abstract
A placebo was substituted for maintenance antiparkinson drug in 41 patients who had been given this medication for the control of phenothiazine-induced extra-pyramidal reactions. These reactions did not recur in 24 of the 41 patients (59%). Although recurrence rates will vary with different clinical situations, it is probable that a large proportion of patients do not require maintenance antiparkinson drug for continued clinical control of phenothiazine-induced extra-pyramidal reactions. Trials are recommended to determine which patients should or should not continue to receive maintenance antiparkinson drug.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
